Avai Bio (AVAI) Common Equity (2018 - 2025)

Avai Bio has disclosed Common Equity across 8 years of filings, most recently posting -$2.8 million for Q4 2025.

• Common Equity for Q4 2025 came in at -$2.8 million, down 230.85% year-over-year; the trailing twelve-month figure through Dec 2025 was -$2.8 million (down 230.85% YoY), and the FY2025 annual result was -$1.6 million, down 6.63% from the prior year.
• Common Equity came in at -$2.8 million for Q4 2025 at Avai Bio, down from -$2.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.1 million in Q4 2024 to a low of -$2.8 million in Q4 2025.
• The 5-year median for Common Equity is -$586370.5 (2022), against an average of -$740898.1.
• Peak annual rise in Common Equity reached 402.29% in 2021, while the deepest fall reached 768.79% in 2021.
• Avai Bio's Common Equity stood at -$416940.0 in 2021, then retreated by 29.39% to -$539482.0 in 2022, then sank by 159.67% to -$1.4 million in 2023, then jumped by 252.45% to $2.1 million in 2024, then tumbled by 230.85% to -$2.8 million in 2025.
• The last three Common Equity figures came in at -$2.8 million (Q4 2025), -$2.3 million (Q3 2025), and -$2.0 million (Q2 2025), per Business Quant data.